Benralizumab as a steroid-sparing rescue therapy in ANCA-negative eosinophilic granulomatosis with polyangiitis: real-world experience from three cases and review of the literature
Agata Sebastian, Joanna Kosałka-Węgiel, Mateusz Puchala, Katarzyna Życińska, Bogdan Kolarz, Edyta Bieniasz-Pawlik, Mariusz Korkosz · 2026
Read Benralizumab as a steroid-sparing rescue therapy in ANCA-negative eosinophilic granulomatosis with polyangiitis: real-world experience from three cases and review of the literature by Agata Sebastian, Joanna Kosałka-Węgiel, Mateusz Puchala, Katarzyna Życińska, Bogdan Kolarz, Edyta Bieniasz-Pawlik, Mariusz Korkosz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13275739.txt.
Description
Agata Sebastian and co-authors present a 2026 case series and literature review on a rare blood vessel disease. The disease, called EGPA for short, swells small vessels and is driven by eosinophils, a type of white blood cell. Many patients stay dependent on steroid drugs despite standard treatment.
The authors describe three patients whose tests lacked a marker called ANCA and who received benralizumab, a drug that wipes out eosinophils. All three had severe asthma and disease in several organs. After treatment, eosinophil counts fell fast and stayed low, asthma and skin and nose symptoms eased, and heart lesions cleared in one patient after six months. Two patients stopped steroids and one cut to a low dose. No serious side effects appeared, though the authors call for larger trials.
Catalog record
| CREATOR | Agata Sebastian, Joanna Kosałka-Węgiel, Mateusz Puchala, Katarzyna Życińska, Bogdan Kolarz, Edyta Bieniasz-Pawlik, Mariusz Korkosz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26680 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |